Cargando…
Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis
INTRODUCTION: Juvenile idiopathic arthritis (JIA) is a disease associated with loss of bone mass, deterioration in bone mass quality and an increased risk of fractures. The objective of this study was to evaluate factors that predict bone mineral density (BMD) alterations in young adult patients wit...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236454/ https://www.ncbi.nlm.nih.gov/pubmed/25280749 http://dx.doi.org/10.1186/s13075-014-0460-x |
_version_ | 1782345165940195328 |
---|---|
author | Brabnikova-Maresova, Kristyna Jarosova, Katerina Pavelka, Karel Stepan, Jan J |
author_facet | Brabnikova-Maresova, Kristyna Jarosova, Katerina Pavelka, Karel Stepan, Jan J |
author_sort | Brabnikova-Maresova, Kristyna |
collection | PubMed |
description | INTRODUCTION: Juvenile idiopathic arthritis (JIA) is a disease associated with loss of bone mass, deterioration in bone mass quality and an increased risk of fractures. The objective of this study was to evaluate factors that predict bone mineral density (BMD) alterations in young adult patients with active JIA before and during therapy with tumour necrosis factor α (TNFα) inhibitors. METHODS: Thirty-one patients (twelve males and nineteen females; mean age =25.1 ± 6.1 years) with active JIA (mean Disease Activity Score in 28 joints (DAS28) =6.36 ± 0.64; mean high-sensitivity C-reactive protein (hsCRP) =18.36 ± 16.95 mg/L) were investigated. The control group consisted of 84 healthy individuals matched by sex and age. BMD, bone turnover markers and serum concentrations of soluble receptor activator of nuclear factor κB ligand, osteoprotegerin, dickkopf Wnt signalling pathway inhibitor 1 (Dkk1) and sclerostin were evaluated. RESULTS: Baseline BMD values in the lumbar spine, proximal femur, femoral neck and distal radius were significantly lower in patients with JIA compared to healthy control participants. Baseline sclerostin serum concentrations were significantly higher in patients with JIA compared to control participants. After 2 years of treatment with TNFα inhibitors, BMD was significantly increased in the lumbar spine. This increase correlated with a drop in DAS28 score. A statistically significant correlation between hsCRP and Dkk1 was found at baseline, as well as during the 2-year follow-up period. A significant reduction in serum sclerostin after 1 year of therapy was predictive of a drop in DAS28 score observed with a 1-year delay after reduction of serum sclerostin. CONCLUSION: A significant correlation between the sclerostin serum concentration and the number of tender and swollen joints, but not BMD, supports the hypothesis that chondrocytes and cells of the subchondral bone may contribute to circulating sclerostin in JIA. |
format | Online Article Text |
id | pubmed-4236454 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42364542014-11-19 Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis Brabnikova-Maresova, Kristyna Jarosova, Katerina Pavelka, Karel Stepan, Jan J Arthritis Res Ther Research Article INTRODUCTION: Juvenile idiopathic arthritis (JIA) is a disease associated with loss of bone mass, deterioration in bone mass quality and an increased risk of fractures. The objective of this study was to evaluate factors that predict bone mineral density (BMD) alterations in young adult patients with active JIA before and during therapy with tumour necrosis factor α (TNFα) inhibitors. METHODS: Thirty-one patients (twelve males and nineteen females; mean age =25.1 ± 6.1 years) with active JIA (mean Disease Activity Score in 28 joints (DAS28) =6.36 ± 0.64; mean high-sensitivity C-reactive protein (hsCRP) =18.36 ± 16.95 mg/L) were investigated. The control group consisted of 84 healthy individuals matched by sex and age. BMD, bone turnover markers and serum concentrations of soluble receptor activator of nuclear factor κB ligand, osteoprotegerin, dickkopf Wnt signalling pathway inhibitor 1 (Dkk1) and sclerostin were evaluated. RESULTS: Baseline BMD values in the lumbar spine, proximal femur, femoral neck and distal radius were significantly lower in patients with JIA compared to healthy control participants. Baseline sclerostin serum concentrations were significantly higher in patients with JIA compared to control participants. After 2 years of treatment with TNFα inhibitors, BMD was significantly increased in the lumbar spine. This increase correlated with a drop in DAS28 score. A statistically significant correlation between hsCRP and Dkk1 was found at baseline, as well as during the 2-year follow-up period. A significant reduction in serum sclerostin after 1 year of therapy was predictive of a drop in DAS28 score observed with a 1-year delay after reduction of serum sclerostin. CONCLUSION: A significant correlation between the sclerostin serum concentration and the number of tender and swollen joints, but not BMD, supports the hypothesis that chondrocytes and cells of the subchondral bone may contribute to circulating sclerostin in JIA. BioMed Central 2014-10-04 2014 /pmc/articles/PMC4236454/ /pubmed/25280749 http://dx.doi.org/10.1186/s13075-014-0460-x Text en © Brabnikova-Maresova et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Brabnikova-Maresova, Kristyna Jarosova, Katerina Pavelka, Karel Stepan, Jan J Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis |
title | Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis |
title_full | Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis |
title_fullStr | Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis |
title_full_unstemmed | Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis |
title_short | Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis |
title_sort | serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236454/ https://www.ncbi.nlm.nih.gov/pubmed/25280749 http://dx.doi.org/10.1186/s13075-014-0460-x |
work_keys_str_mv | AT brabnikovamaresovakristyna serumsclerostininhighactivityadultpatientswithjuvenileidiopathicarthritis AT jarosovakaterina serumsclerostininhighactivityadultpatientswithjuvenileidiopathicarthritis AT pavelkakarel serumsclerostininhighactivityadultpatientswithjuvenileidiopathicarthritis AT stepanjanj serumsclerostininhighactivityadultpatientswithjuvenileidiopathicarthritis |